tirzepatide compounding fda confirms shortage is still over, gives compounders a grace period TIRZEPATIDE - Med Spa Treatments
Description
As demand for GLP-1 weight-loss solutions grows, prescription-free alternatives are getting a lot of attention

Data from the UKs medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has revealed that since glucagon-like peptide-1 receptor agonists (GLP-1) were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines

UMMH posted $86M in operating losses in just H1 ($40M health safety net funding shortfall)

Unlike injectable semaglutide or tirzepatide, this is a once-daily pilland if it progresses successfully through development, it could change patient access.
Tirzepatide is a dual GLP-1 and GIP receptor agonist that requires careful patient education and medical supervision
